基于裂解物的人白细胞抗原交叉配型是确定移植禁忌症的可靠方法吗?

IF 0.2 Q4 TRANSPLANTATION

Indian Journal of Transplantation Pub Date : 2023-01-01 DOI:10.4103/ijot.ijot_53_23

Shruti Tapiawala, Suchita Jogale, Bharat V. Shah, Anuradha Raman

{"title":"基于裂解物的人白细胞抗原交叉配型是确定移植禁忌症的可靠方法吗?","authors":"Shruti Tapiawala, Suchita Jogale, Bharat V. Shah, Anuradha Raman","doi":"10.4103/ijot.ijot_53_23","DOIUrl":null,"url":null,"abstract":"The presence of preformed cytotoxic donor-specific antibodies (DSAs) has been associated with inferior allograft outcomes in the immediate posttransplant period. Since the 1970s, the primary method for determining the presence of DSAs has been the complement-dependent cytotoxicity crossmatch. Solid phase assays on the Luminex platform were introduced in India in 2010 in the form of human leukocyte antigen antibody screening, single antigen bead (SAB) assay and lysate-based crossmatch (LumXM) to identify low titer antibodies, which are deleterious to allograft. Instead of SAB, LumXM has been popularly used in India to identify DSAs and also called DSA crossmatch, which is not recommended or validated in International literature for denying or accepting to transplant a patient due to its fallacies. We are reporting three cases which showcase the flawed nature of this test and the implications of this test on day to day practice in transplantation.","PeriodicalId":37455,"journal":{"name":"Indian Journal of Transplantation","volume":"60 3 1","pages":"0"},"PeriodicalIF":0.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is Lysate-based Human Leukocyte Antigen Crossmatch a Reliable Method to Contraindicate a Transplant?\",\"authors\":\"Shruti Tapiawala, Suchita Jogale, Bharat V. Shah, Anuradha Raman\",\"doi\":\"10.4103/ijot.ijot_53_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The presence of preformed cytotoxic donor-specific antibodies (DSAs) has been associated with inferior allograft outcomes in the immediate posttransplant period. Since the 1970s, the primary method for determining the presence of DSAs has been the complement-dependent cytotoxicity crossmatch. Solid phase assays on the Luminex platform were introduced in India in 2010 in the form of human leukocyte antigen antibody screening, single antigen bead (SAB) assay and lysate-based crossmatch (LumXM) to identify low titer antibodies, which are deleterious to allograft. Instead of SAB, LumXM has been popularly used in India to identify DSAs and also called DSA crossmatch, which is not recommended or validated in International literature for denying or accepting to transplant a patient due to its fallacies. We are reporting three cases which showcase the flawed nature of this test and the implications of this test on day to day practice in transplantation.\",\"PeriodicalId\":37455,\"journal\":{\"name\":\"Indian Journal of Transplantation\",\"volume\":\"60 3 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ijot.ijot_53_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"TRANSPLANTATION\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijot.ijot_53_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"TRANSPLANTATION","Score":null,"Total":0}

引用次数: 0

摘要

预先形成的细胞毒性供体特异性抗体(dsa)的存在与同种异体移植物移植后立即出现的不良结果有关。自20世纪70年代以来，确定dsa存在的主要方法是补体依赖性细胞毒性交叉匹配。Luminex平台上的固相检测于2010年在印度引入，其形式包括人白细胞抗原抗体筛选、单抗原珠(SAB)检测和基于裂解物的交叉匹配(LumXM)，以识别对同种异体移植物有害的低效价抗体。代替SAB, LumXM在印度被广泛用于识别DSA，也被称为DSA交叉匹配，由于其谬论，在国际文献中不推荐或验证拒绝或接受患者移植。我们报告了三个病例，这些病例显示了这种测试的缺陷性质以及这种测试在移植的日常实践中的意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Is Lysate-based Human Leukocyte Antigen Crossmatch a Reliable Method to Contraindicate a Transplant?

The presence of preformed cytotoxic donor-specific antibodies (DSAs) has been associated with inferior allograft outcomes in the immediate posttransplant period. Since the 1970s, the primary method for determining the presence of DSAs has been the complement-dependent cytotoxicity crossmatch. Solid phase assays on the Luminex platform were introduced in India in 2010 in the form of human leukocyte antigen antibody screening, single antigen bead (SAB) assay and lysate-based crossmatch (LumXM) to identify low titer antibodies, which are deleterious to allograft. Instead of SAB, LumXM has been popularly used in India to identify DSAs and also called DSA crossmatch, which is not recommended or validated in International literature for denying or accepting to transplant a patient due to its fallacies. We are reporting three cases which showcase the flawed nature of this test and the implications of this test on day to day practice in transplantation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Indian Journal of Transplantation Medicine-Transplantation

CiteScore

0.40

自引率

33.30%

发文量

审稿时长

21 weeks

期刊介绍： Indian Journal of Transplantation, an official publication of Indian Society of Organ Transplantation (ISOT), is a peer-reviewed print + online quarterly national journal. The journal''s full text is available online at http://www.ijtonline.in. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. It has many articles which include original articIes, review articles, case reports etc and is very popular among the nephrologists, urologists and transplant surgeons alike. It has a very wide circulation among all the nephrologists, urologists, transplant surgeons and physicians iinvolved in kidney, heart, liver, lungs and pancreas transplantation.